Sinovac Biotech Ltd.: 5%+ holders

Sinovac Biotech Ltd. has 9 Schedule 13D or 13G filings on record since 2025-07-01. 5 holders' latest filing reports 5% or more of common shares, par value us$0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Purpose of Transaction (Item 4)

1Globe Capital LLC

Item 4 of the Schedule 13D is hereby amended and supplemented as follows: On July 25, 2025, Vivo Capital Surplus Fund VIII, L.P. ("Vivo Fund VIII") filed an amended complaint (the "Amended Complaint") with the U.S. District Court for the Commonwealth of Massachusetts in the civil action initiated by Vivo Fund VIII on April 14, 2025 and previously disclosed in Amendment No. 6 to the Schedule 13D (the "Vivo Action"). In the Amended Complaint, Vivo Fund VIII alleges a disclosure violation claim under Section 13(d) of the Securities Exchange Act of 1934, repeating in a single count the allegations that appeared in its original complaint. Among other things, Vivo Fund VIII alleges that (1) Dr. Li has not filed a Schedule 13D and as a result investors do not know how many Sinovac shares he beneficially owns; (2) 1Globe Capital LLC disclaims in its Schedule 13D Amendments any "arrangement" or "agreement" with OrbiMed Advisors LLC and OrbiMed Capital LLC (collectively, "OrbiMed"), but has not disclosed whether it and OrbiMed have any "understandings" or "relationship"; and (3) the Schedule 13D Amendments include no disclosure regarding defendants and OrbiMed's "ongoing plans and proposals to regain their control of Sinovac," now that Vivo Fund VIII alleges that there was a change in control at the Special Meeting (as defined and discussed below). The foregoing summary of the Amended Complaint does not purport to be complete and is qualified in its entirety by the full copy of …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-09-12; the filing has the rest

Vivo Capital VIII, LLC

Item 4 is hereby supplemented and amended by adding the following: On May 19, 2025, the Issuer gave notice of a Special Meeting of Shareholders to be held on July 8, 2025 and announced an intention to exclude shares held by the Reporting Persons and another investor from the vote. On May 30, 2025, the Issuer filed an application for an injunction in the High Court of Antigua and Barbuda seeking an order prohibiting the Reporting Persons and the other investor from voting their shares at the Special Meeting. The Reporting Persons have opposed such an injunction in the High Court and the Court of Appeal of the Eastern Caribbean Supreme Court, and, on July 8, 2025, the Court of Appeal issued an order staying execution of an injunction from the High Court. In light of the Court of Appeal's stay order, the Reporting Persons exercised their rights as registered shareholders of Sinovac to vote by proxy in support of SAIF's proposed slate of directors at the Special Meeting, including Mr. Shan Fu. The Issuer disclosed on July 10, 2025 that a new Board of Directors consisting of the SAIF nominated slate, including Mr. Fu was elected at the Special Meeting of the Company held on July 8, 2025. Mr. Fu has accepted the appointment and plans to participate in the future governance of Sinovac as a member of the newly elected Board of Directors as of July 8, 2025. The Reporting Person has continued to engage in discussions with other shareholders about the board, the future of the …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-07-11; the filing has the rest

Advantech Capital L.P.

Item 4 is hereby supplemented and amended by adding the following: On July 7, 2025, the High Court of Antigua and Barbuda granted an interim injunction prohibiting the Reporting Persons and certain other shareholders from voting their shares at the Special Meeting (the "Injunction Order"). On July 8, 2025, the Court of Appeal of the Eastern Caribbean Supreme Court issued an order staying the Injunction Order (the "Stay Order"). After the Court of Appeal issued the Stay Order, the Special Meeting of Shareholders of the Issuer requisitioned by SAIF Partners IV L.P. ("SAIF") (the "Special Meeting") was convened. Mr. Chiang Li delivered a short statement and then purported to adjourn the Special Meeting. The Reporting Persons understand that the shareholders attending the Special Meeting then continued with the Special Meeting chaired by an incumbent director of the Issuer. The Reporting Persons voted their shares by proxy in favor of SAIF's proposals at the Special Meeting. The Reporting Persons understand that the shareholders of the Issuer approved both of SAIF's proposals at the Special Meeting and elected the nominees proposed by SAIF, including Mr. Yumin Qiu, a partner of Advantech Capital, to be the directors of the Issuer. Mr. Yumin Qiu accepted the appointment and intends to serve as a member of the board of directors of the Issuer. The Reporting Persons understand that on July 10, 2025, the previous directors removed at the Special Meeting issued a press release …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-07-14; the filing has the rest

Weidong Yin

Item 4 is hereby amended and supplemented to add the following: The Issuer announced on July 10, 2025 a new board of directors of the Issuer (the "Board"), comprising Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Mr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y Yan (as Chairman of the Board) and the Reporting Person. The Reporting Person has accepted the appointment and plans to participate in the future governance of the Issuer as a member of the newly Board. Except as set forth in this Item 4, the Reporting Person has no present plan or intention that would resu lt in or relate to the listed transactions described in Item 4 of Schedule 13D. The Reporting Person has engaged and will continue to engage in discussions with other shareholders of the Issuer regarding the Board, the corporate governance and similar matters that the Reporting Person believes would increase shareholder value, and depending on the outcome of the discussion, the Reporting Person may pursue plans or proposals that relate to or would result in any of the matters set forth in clauses (a)-(j) of Item 4 of Schedule 13D. The filing of this Amendment shall not be construed as an admission that the Reporting Person, on the one hand, and any other shareholders of the Issuer and their affiliates, on the other hand, are a group, or have agreed to act as a group with each other for purposes of Section 13(d) of the Act or for any other purpose. The Reporting Person …The first part of Item 4 of the SCHEDULE 13D/A filed 2025-07-15; the filing has the rest

Timeline

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes